Chitosan-derivative compounds and methods of controlling microbial populations

Inventors

Baker, Shenda • Wiesmann, William P.

Assignees

Synedgen Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9732164-B2

Patent

Publication Date

2017-08-15

Expiration Date


Abstract

The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.

Core Innovation

The disclosure relates to functionalized chitosan derivatives having protonated, positively charged functional groups, including chitosan-arginine, chitosan-guanidine, and chitosan conjugates with natural or unnatural amino acids. The compounds are described as controlling microbial populations, including bacteria, viruses, biofilms, gram+ and gram− bacteria, and mycoplasma/viruses, with antimicrobial performance linked to protonated and positively charged functional groups.

The disclosure describes defined degrees of deacetylation and functionalization, including parameters p, q, m, and in some embodiments n, with constraints such as p+q+m=1 and p+q+m+n=1, together with fractional functionalization limits. It further states that solubility at physiologic pH is tuned in the range of pH 6.8-7.4, and that antimicrobial selectivity is controlled by molecular weight and charge density/placement produced by functionalization degree and polymer structure parameters.

The compounds further include co-derivatives with Y payloads such as iron chelating molecules, antioxidants, and fluorescent markers, together with charged natural amino-acid functionalizations such as lysine, histidine, aspartic acid, and glutamic acid. The disclosure also describes functionalization architectures, including random distribution along the chitosan backbone, and formulations as powders, films, coatings, gels, and nanoparticles, including coatings on medical surfaces and textiles.

The disclosure reports in vitro and in vivo examples showing bactericidal/bacteriostatic activity dependent on functionalization and dose, limited cytotoxicity to mammalian cells, and improved survivability in infected burn models. It also describes prevention of biofilm formation or inactivation of virions via binding, and references structural definitions for how arginine attachment occurs and how functional groups are distributed along the chitosan backbone while maintaining protonated, positively charged character.

Claims Coverage

The provided independent claims cover two distinct method approaches for making Formula (I) compounds, each with defined composition constraints using m and q and the relationship p+q+m=1. Across the two independent claims, the inventive features focus on the reaction sequence and, in one claim, the single reaction vessel integration with activation and coupling reagents, followed by acid addition.

Making Formula (I) through sequential Formula (II) and acid reaction

A method of making a compound of Formula (I) by reacting a compound of Formula (II) with an acid, wherein m is 0.02-0.50, q is 0.50-0.01, and p+q+m=1, and wherein the compound of Formula (II) is made by reacting a compound of Formula (III) with a compound of Formula (IV).

Single reaction vessel making of Formula (I) using activation reagent and coupling agent followed by acid

A method of making a compound of Formula (I) in a single reaction vessel by reacting a compound of Formula (V), wherein m is 0.02-0.50, q is 0.50-0.01, and p+q+m=1, with Formula (III) in the presence of an activation reagent and a coupling agent, followed by addition of an acid, thereby providing the compound of Formula (I).

The claim coverage centers on parameterized functionalized compounds defined by m and q with p+q+m=1, and on making Formula (I) via acid addition from an intermediate (Formula (II)) in one approach or via an integrated single-vessel workflow using an activation reagent and coupling agent followed by acid in the other approach.

Stated Advantages

Improved antimicrobial performance against bacteria, viruses, and biofilms.

Antimicrobial selectivity is controlled by functionalization degree, molecular weight, and charge density/placement.

Solubility is tuned at physiologic pH in the range of pH 6.8-7.4.

Limited cytotoxicity to mammalian cells.

Improved survivability in infected burn models.

Controls chitosan molecular weight distribution.

Documented Applications

Control of microbial populations, including bacteria, viruses, and biofilms.

Broad targeting across gram+ and gram− bacteria and mycoplasma/viruses.

Prevention of biofilm formation or inactivation of virions via binding.

Formulation as powders, films, coatings, gels, and nanoparticles.

Coatings on medical surfaces and textiles.

Demonstrated antibacterial activity across a gut pH range.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.